We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fecal Hemoglobin Stability Evaluated for FITs

By LabMedica International staff writers
Posted on 31 Oct 2017
Print article
Image: The hema-Screen Specific kit for the rapid and qualitative determination of Occult Human Blood in fecal samples (Photo courtesy of Immunostics).
Image: The hema-Screen Specific kit for the rapid and qualitative determination of Occult Human Blood in fecal samples (Photo courtesy of Immunostics).
Screening with guaiac-based fecal occult blood tests (gFOBT), followed by colonoscopy for patients who test positive, has been associated with a reduction of 15% to 33% in colorectal cancer (CRC)–related mortality.

Fecal immunochemical test (FIT) methods have been developed. These immunoassays form an antibody antigen complex with the globin moiety of human hemoglobin (Hb) to generate either an immunoturbidimetric signal, which can be measured quantitatively or by lateral-flow immunochromatographic analysis, a qualitative band that can be detected visually.

A large team of scientists collaborating with those at Sunnybrook Research Institute (Toronto, ON, Canada) implemented a novel, standardized method to compare Hb stability across various fecal immunochemical tests. The stability of Hb was analyzed in collection devices inoculated with Hb-spiked feces and (1) stored at various temperatures (frozen, refrigerated, ambient, and elevated) for more than 60 days; (2) after undergoing three controlled, freeze-thaw cycles; and (3) after being transported by courier or postal services in uncontrolled temperature conditions from three locations in Ontario, Canada, to a central testing center. The team compared the stability of Hb across five different immunochemical kits and one guaiac kit.

The scientists found that the stability of Hb varied with time and temperature and by kit. Lower Hb recoveries occurred with increasing temperature and increasing time from sample collection to testing. Refrigeration provided the best stability, although results varied across kits, from 4.2 days to more than 60 days before a pre-specified threshold with less than 70% probability of the test results remaining positive was reached.

Freeze-thaw stability varied across kits and cycles. Hb recoveries from Hemoglobin NS-Plus, was 91.7% to 95.4%; while for OC-Sensor Diana, the Hb recovery was 57.6% to 74.9%. Agreement regarding Hb levels before and after transportation varied across kits, from 57% to 100%. The scientists found that the Hema-Screen SPECIFIC, was the best performer among the qualitative kits.

The authors concluded that important differences in Hb stability were found across the included fecal immunochemical tests and these findings should inform practice-based and population-based colorectal cancer screening. The study was published on October 2, 2017, in the journal Archives Of Pathology & Laboratory Medicine.

Related Links:
Sunnybrook Research Institute

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Gold Member
Troponin T QC
Troponin T Quality Control
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
3-Position Stirrer
ST-200 and SHP-200 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.